Schnitzler syndrome: case report, the experience with glucocorticoid and anakinra (Kineret^TM) therapies and monitoring of systemic cytokine response

Česká verzia

Authors: P. Szturz ¹; Z. Adam ¹; M. Klabusay ¹; Z. Fojtík ¹; Z. Kadaňka ²; O. Stehlíková ¹; J. Chovancová ³; L. Kalvodová ¹; D. Čorbová ⁴; K. Starý ⁵; J. Neubauer ⁶; J. Prášek ⁷; R. Koukalová ⁸; Z. Řehák ⁸; R. Hájek ¹; J. Mayer ¹
Authors place of work: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jiří Vorlíček, CSc. ¹; Neurologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Josef Bednařík, CSc. ²; Lékařská fakulta MU Brno, děkan prof. MU Dr. Jiří Mayer, CSc. ³; Dermatovenerologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednostka prof. MU Dr. Alena Pospíšilová, CSc. ⁴; Interní hepatogastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jan Lata, CSc. ⁵; Radiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Vlastimil A. Válek, CSc. ⁶; Klinika nukleární medicíny Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta doc. MU Dr. Jiří Prášek, CSc. ⁷; Oddělení nukleární medicíny, PET Centrum Masarykova onkologického ústavu Brno, přednosta prim. MU Dr. Karol Bolčák ⁸
Published in the journal: Vnitř Lék 2011; 57(1): 97-112
Category: Case Reports

Summary

Schnitzler syndrome is a rare idiopathic disease characterized by chronic urtica, presence of monoclonal IgM immunoglobuline and further, less common symptoms. This case report describes another case of this disease affecting a male adult born in 1963. The first symptoms, eruptions of non‑pruritic urticarial rash, appeared in this patient at the age of 43. In addition, bone pains (mainly tibias) and joint pains (mainly knees) were present. Later on however, severe attacks of fever, chills and shaking together with bone and joint pains were added to during which new urticarial eruptions appeared. Primarily, the man was followed up without any substantial therapeutic results at a department of dermatovenerology, subsequently, due to a finding of monoclonal IgM κ immunoglobulin (serum concentration 1.9 g/ l) he was referred to our department for the reason of gammopathy being a differential diagnosis. On a CT scan hyperostosis in claviculae and pelvic bones was identified. Also on the CT, an increase in cortical thickness was described in the long bones of the lower extremities, where areas of technetium pyrophosphate accumulation were indentified on a bone scintigraphy. These areas were found in the chest and sacral regions as well. From the blood exams, the proinflammatory status of the organism was apparent (CRP 35.9 mg/ l, erythrocyte sedimentation rate 92 mm/ h, leukocytes 12.4 × 10⁹/ l). After excluding other differential diagnoses, the patient was diagnosed with Schnitzler syndrome. As regards therapy, we made initial use of the effect of corticoids which abated the symptoms, however, these were causing serious adverse reactions in the form of iatrogenous Cushing’s syndrome. The therapy took a turn only after biologic therapy with anakinra (interleukin‑1 receptor antagonist) had started, which minimized the Schnitzler symptoms with very good drug tolerance. In the work we measured serum levels of interleukins for disease activity monitoring. The most sensitive were interleukins IL‑6 and especially IL‑18 the levels of which were the highest at the time of clinical exacerbation of the disease, whereas the levels of IL‑1β and TNF‑α (tumour necrosis factor) were during all measurements below the limit of detection. Concerning the growing numbers of the reports on successful biological therapy with anakinra and our positive experience, we propose that the therapeutic response to anakinra should be included within the diagnostic criteria of Schnitzler syndrome, which is significant above all in differential diagnosis thereof.

Key words:
Schnitzler syndrome – autoinflammatory diseases – monoclonal gammopathy – multiple myeloma – Cushing’s syndrome – interleukins

Zdroje

1. Schnitzler L, Schubert B, Boasson M et al. Urticaire chronique lesions osseuses macroglobulinémie IgM: Maladie de Waldenström? Bull Soc Fr Dermatol Syph 1974; 81: 363– 366.

2. Lipsker D, Veran Y, Grunenberger F et al. The Schnitzler syndrome: four new cases and review of the literature. Medicine (Baltimore) 2001; 80: 37– 44.

3. Besada E, Nossent H. Dramatic response to IL1– RA treatment in longstanding multidrug resistant Schnitzler’s syndrome: a case report and literature review. Clin Rheumatol 2010; 29: 567– 571.

4. Klener P et al. Cytokiny ve vnitřním lékařství. Praha: Grada Publishing 1997.

5. Kluger N, Bessis D, Guillot B. Tocilizumab as a potential treatment in Schnitzler syndrome. Med Hypotheses 2009; 72: 479– 480.

6. Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev 2003; 24: 523– 538.

7. Marek J. Léčba kortikoidy. Doporučené postupy. Projekt MZ ČR zpracovaný ČLS JEP za podpory grantu IGA MZ ČR 5390– 3. Praha: ČLS JEP 2002.

8. Brunová J, Bruna J. Klinická endokrinologie a zobrazovací diagnostika endokrinopatií. Praha: Maxdorf 2009.

9. Martinez- Taboada VM, Fontalba A, Blanco R et al. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum 2005; 52: 2226– 2227.

10. Loock J, Lamprecht P, Timmann C et al. Genetic predisposition (NLRP3 V198M mutation) for IL-1- mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol 2010; 125: 500– 502.

11. Pizzirani C, Falzoni S, Govoni M et al.Dysfunctional inflammasome in Schnitzler’s syndrome. Rheumatology (Oxford) 2009; 48: 1304– 1308.

12. Asahina A, Sakurai N, Suzuki Y et al. Schnitzler’s syndrome with prominent neutrophil infiltration misdiagnosed as Sweet’s syndrome: a typical example of urticarial neutrophilic dermatosis. Clin Exp Dermatol 2010; 35: e123– e126.

13. Migliorini P, Del Corso I, Tommasi C et al. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? Eur Cytokine Netw 2009; 20: 108– 111.

14. Tomková H, Shirafuji Y, Arata J. Schnitzler’s syndrome versus adult onset Still’s disease. Eur J Dermatol 1998; 8: 118– 121.

15. SanMartín O, Febrer I, Botella R et al. Urticarial lesions and monoclonal IgM gammopathy. Schnitzler’s syndrome. Arch Dermatol 1994; 130: 1193– 1198.

16. Almerigogna F, Giudizi MG, Cappelli F et al. Schnitzler’s syndrome: what’s new? J Eur Acad Dermatol Venereol 2002; 16: 214– 219.

17. Kropp JD, Czarnetzki BM. Urticaria – vasculitis und Schnitzler’s syndrome. Allergologie 1994; 17: S17– S20.

18. Berdy SS, Bloch KJ. Schnitzler’s syndrome: a broader clinical spectrum. J Allergy Clin Immunol 1991; 87: 849– 854.

19. Borradori L, Rybojad M, Puissant A et al. Urticarial vasculitis associated with monoclonal IgM gammopathy, Schnitzler’s syndrome. Brit J Dermatol 1990; 123: 113– 118.

20. Morita A, Sakakibara S, Yokota M et al. A case of urticarial vasculitis associated with macroglobulinemia (Schnitzler’s syndrome). J Dermatol 1995; 22: 32– 35.

21. Lautenschlager S, Itin PH. Schnitzler’s syndrome. Hautarzt 1993; 44: 781– 784.

22. Janier M, Bonvalet D, Blanc MF et al. Chronic urticaria and macroglobulinemia (Schnitzler’s syndrome): report of two cases. J Am Acad Dermatol 1989; 20: 206– 211.

23. Olsen E, Førre O, Lea T et al. Unique antigenic determinants used as markers in a patient with macroglobulinemia urticaria. Similar idiotypes demonstrated in the skin and on peripheral blood lymphocytes. Acta Med Scand 1980; 207: 379– 384.

24. de Koning HD, Bodar EJ, van der Meer JW et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137– 148.

25. de Koning HD, van der Meer JW, Simon A. Comment on: Schnitzler’s syndrome – exacerbation after anti-TNF treatment. Rheumatology (Oxford) 2007; 46: 1741.

26. Ščudla V, Adam Z, Ščudlová M. Současné možnosti diagnostiky a léčby anémie chronických chorob. Vnitř Lék 2001; 47: 400– 406.

27. Lecompte M, Blais G, Bisson G et al. Schnitzler’s syndrome. Skeletal Radiol 1998; 27: 294– 296.

28. De Saint- Pierre V, Ehrhart A, Baron D et al. Systemic urticaria, sclerosing osteopathy, monoclonal gammopathy (Schnitzler’s syndrome). Apropos of a case. Rev Rhum Mal Osteoartic 1992; 59: 288– 292.

29. De Waele S, Lecouvet FE, Malghem J et al. Schnitzler’s syndrome: an unusual cause of bone pain with suggestive imaging features. AJR Am J Roentgenol 2000; 175: 1325– 1327.

30. Flórez AF, Gallardo Agromayor E, García-Barredo R et al. Radiological aid to clinical diagnosis of Schnizler’s syndrome: multimodality imaging approach. Clin Rheumatol 2008; 27: 107– 110.

31. Ferrando FJ, Pujol J, Hortells JL et al. Schnitzler’s syndrome: report of a case with bone osteolysis. J Investig Allergol Clin Immunol 1994; 4: 203– 205.

32. Bertrand A, Feydy A, Belmatoug N et al. Schnitzler’s syndrome: 3-year radiological follow-up. Skeletal Radiol 2007; 36: 153– 156.

33. Dupuy O, Pinede L, Coppere B et al. Schnitzler’s syndrome with stable course over a 18-year period. Report of a case. Presse Med 1995; 24: 1402.

34. Adam Z, Krejčí M, Vorlíček J. Maligní krevní nemoci. Praha: Grada Publishing 2008.

35. Adam Z. Diferenciální diagnostika monoklonálních gamapatií. Intern Med pro Prax 2004; 5: 279– 283.

36. Šedivá A. Poruchy regulace zánětu a periodické horečky. Alergie 2006; 1: 36– 41.

37. Adam Z, Šmardová J, Ščudla V. Waldenströmova makroglobulinemie – klinické projevy, diferenciální diagnostika a prognóza nemoci. Vnitř Lék 2007; 53: 1325– 1337.

38. Pujol RM, Barnadas MA, Brunet S et al. Urticarial dermatosis associated with Waldenström’s macroglobulinemia. J Am Acad Dermatol 1989; 20: 855– 857.

39. Lipsker D, Cribier B, Maloisel F et al. Chronic urticaria and IgA myeloma. Acta Derm Venereol 1998; 78: 395.

40. Karakelides M, Monson KL, Volcheck GW et al. Monoclonal gammopathies and malignancies in patients with chronic urticaria. Int J Dermatol 2006; 45: 1032– 1038.

41. Lipsker D, Boeckler P. Cutaneous manifestations of paraproteinemia and their mechanisms. Presse Med 2007; 36: 1135– 1140.

42. Jarošová K. Stillova choroba v dospělosti. Čes Revmatol 2006; 14: 159– 163.

43. Gilson M, Abad S, Larroche C et al. Treatment of Schnitzler’s syndrome with anakinra. Clin Exp Rheumatol 2007; 25: 931.

44. Glaser RL, Goldbach- Mansky R. The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies. Curr Allergy Asthma Rep 2008; 8: 288– 298.

45. Padeh S. Periodic fever syndromes. Pediatr Clin North Am 2005; 52: 577– 609.

46. Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol 2008; 144: 392– 402.

47. Doutre MS, Beylot C. Chronic urticaria and monoclonal IgM: treatment with ibuprofen. J Am Acad Dermatol 1990; 22: 143– 144.

48. Obořilová A, Adam Z. Schnitzler’s syndrome. Vnitř Lék 1998; 44: 423– 427.

49. Machet L, Vaillant L, Machet MC et al. Schnitzler’s syndrome and associated with pseudoxanthoma elasticum. Acta Derm Venereol (Stockholm) 1991; 72: 22– 24.

50. Lebbe C, Rybojad M, Klein F et al. Schnitzler’s syndrome with sensorimotor neuropathy. J Am Acad Dermatol 1994; 30: 316– 318.

51. de Koning HD, Bodar EJ, Simon A et al. Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome. Ann Rheum Dis 2006; 65: 542– 544.

52. Schneider SW, Gaubitz M, Luger TA et al. Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 2007; 56 (Suppl 5): S120– S122.

53. Crouch R, Akhras V, Sarkany R. Schnitzler’s syndrome: successful treatment with anakinra. Australas J Dermatol 2007; 48: 178– 181.

54. Eiling E, Möller M, Kreiselmaier I et al. Schnizler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 2007; 57: 361– 364.

55. Klemmer N, Lenain P, Balguerie X et al. Effectiveness of anti-IL1 in Schnizler’s syndrome. Jt Bone Spine 2007; 74: 509– 510.

56. Thonhoffer R, Uitz E, Graninger W. Schnitzler’s syndrome – exacerbation after anti-TNF treatment. Rheumatology 2007; 46: 1041– 1042.

57. Eiling E, Schröder JO, Gross WL et al. The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy – an autoinflammatory syndrome? J Dtsch Dermatol Ges 2008; 6: 626– 631.

58. Devlin LA, Wright G, Edgar JD. A rare cause of a common symptom, Anakinra is effective in the urticaria of Schnitzler Syndrome: a case report. Cases J 2008; 1: 348.

59. Kluger N, Rivière S, Guillot B et al. Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory Schnitzler’s syndrome. Acta Derm Venereol 2008; 88: 287– 288.

60. Frischmeyer- Guerrerio PA, Rachamalla R, Saini SS. Remission of Schnitzler syndrome after treatment with anakinra. Ann Allergy Asthma Immunol 2008; 100: 617– 619.

61. Adam Z, Krejčí M, Pour L. Schnitzlerův syndrom – popis čtrnáctiletého průběhu nemoci a přehled informací o této nemoci. Vnitř Lék 2008; 54: 1140– 1153.

62. Saiz E, Gálvez J, Mora A et al. Sindrome de Schnitzler y anakinra. Med Clin (Barc) 2008; 130: 357– 358.

63. Lazarevic V, Markuszewska A, Stenberg B et al. Schnitzlers syndrome – okänt, sällsynt med behandlingsbart. Läkartidningen 2008; 105: 3348– 3351.

64. Gallo R, Sabroe RA, Black AK et al. Schnitzler’s syndrome: no evidence for autoimmune basis in two patients. Clin Exp Dermatol 2000; 25: 281– 284.